Class Action Lawsuit Filed Against Aldeyra Therapeutics

Gainey McKenna & Egleston announces lawsuit over inconsistent clinical trial results

Mar. 31, 2026 at 3:59pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a calculator on a clean, monochromatic background, symbolizing the abstract concepts of corporate strategy, finance, and legal risk in the pharmaceutical industry.A legal case over inconsistent clinical trial results exposes the high stakes of transparency in the pharmaceutical industry.NYC Today

A securities class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) on behalf of all persons or entities who purchased the company's securities between November 3, 2023 and March 16, 2026. The lawsuit alleges that Aldeyra failed to disclose to investors that the results of its reproxalap clinical trials were inconsistent, rendering any positive findings unreliable.

Why it matters

The lawsuit claims that when news of Aldeyra's alleged failures to disclose became known, the price of the company's stock dropped significantly, harming investors. This case highlights the importance of transparency and accurate disclosures by public companies, especially regarding the results of clinical trials for new drug candidates.

The details

The complaint alleges that Aldeyra failed to disclose that the results of its reproxalap clinical trials were inconsistent, and that this inconsistency rendered any positive findings from these trials unreliable and not meaningful. As a result, the company's statements about its business, operations, and prospects were allegedly materially false and misleading and/or lacked a reasonable basis.

  • The class period covers the period from November 3, 2023 to March 16, 2026.
  • On March 17, 2026, Aldeyra's stock price dropped $2.99, or approximately 70.7%, to close at $1.24 per share.

The players

Gainey McKenna & Egleston

A law firm that has filed the securities class action lawsuit against Aldeyra Therapeutics.

Aldeyra Therapeutics, Inc.

A biopharmaceutical company that is the defendant in the class action lawsuit.

Got photos? Submit your photos here. ›

What they’re saying

“Investors who purchased or otherwise acquired shares of Aldeyra should contact the Firm prior to the May 29, 2026 lead plaintiff motion deadline.”

— Thomas J. McKenna, Attorney, Gainey McKenna & Egleston

“A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.”

— Gregory M. Egleston, Attorney, Gainey McKenna & Egleston

What’s next

The lead plaintiff motion deadline is set for May 29, 2026.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosures by public companies, especially regarding the results of clinical trials for new drug candidates. Investors will be closely watching the outcome of this case, which could have broader implications for the pharmaceutical industry.